Healthcare - Today Stories

New partnership will provide physician training to drive improved diversity in clinical trials Training program is open to underrepresented groups including female, Black, Native American, Asian, South Asian, Hispanic and non-binary cardiologists Provides opportunities for underrepresented physicians to receive training on the clinical trials process, learn new skills, expand their networks and increase visibility with industry partners ABBOTT PARK, Ill., May 11, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a new partnership with Women as One to launch a new program designed to train more female and underrepresented physicians to pursue clinical trial research and help recruit clinical trial participants from historically underrepresented groups. Women as One is a nonpro…

The three companies will work to accelerate development of automated insulin delivery system for people living with diabetes System is being designed to include Abbott's FreeStyle Libre® 3 sensor, CamDiab's CamAPS FX algorithm, and Ypsomed's mylife™ YpsoPump® Partnership demonstrates the companies' collective desire to drive integrated solutions to help people with diabetes better manage their condition and improve health outcomes BARCELONA, Spain, April 27, 2022 /PRNewswire/ -- Abbott (NYSE: ABT), CamDiab and Ypsomed today announced that they are partnering to develop and commercialize an integrated automated insulin delivery (AID) system to help lessen the burden of round-the-clock diabetes management for people with diabetes. The initial focus of the partnership will be in European co…

Now available for use with both Apple and Android devices, the app helps people track pain relief during the treatment journey with neurostimulation devices Updated app provides doctors with an at-a-glance assessment of their patients while on their treatment journey ABBOTT PARK, Ill., April 25, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that it has launched an upgraded version of its NeuroSphere™ myPath™ digital health app with enhanced functionality that will help doctors more closely track their patients as they trial Abbott neurostimulation devices to address their chronic pain. This upgrade is part of Abbott's commitment to connected care technology and is intended to put people in control of their health and facilitate better communication with their doctors. The digit…

Sierra Oncology’s differentiated momelotinib has the potential to address the critical unmet medical needs of myelofibrosis patients with anaemia Momelotinib complements GSK’s existing expertise in haematology, with Sierra Oncology anticipating US regulatory submission in Q2 this year and EU submission in the second half of 2022 Sales contribution expected to start in 2023 with significant growth potential thereafter Supports development of strong portfolio of new specialty medicines and vaccines GlaxoSmithKline plc (LSE/NYSE: GSK) and Sierra Oncology, Inc (Nasdaq: SRRA) today announced that the companies have entered into an agreement under which GSK will acquire Sierra Oncology, a California-based, late-stage biopharmaceutical company focused on targeted therapies for the treatment of…

The FDA approval of the first dispersible single tablet regimen containing dolutegravir increases age-appropriate treatment options for children living with HIV ViiV Healthcare, the global specialist HIV company majority-owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. (Pfizer) and Shionogi B.V. (Shionogi) as shareholders, has announced that the U.S. Food and Drug Administration (FDA) has approved a new drug application (NDA) for a dispersible tablet formulation of the fixed dose combination of abacavir, dolutegravir and lamivudine for the treatment of pediatric patients weighing 10kgs to <25 kgs with human immunodeficiency virus type 1 (HIV-1). In addition, a supplemental new drug application (sNDA) has been approved for Triumeq tablet, lowering the minimum weight that a child wi…

- Abbott and LISC invest more than $37 million to empower and grow diverse small businesses that provide manufacturing and essential products for healthcare companies - Initiative supports Abbott and LISC's commitment to increase diversity in healthcare and generate jobs and strengthen economies in underinvested communities ABBOTT PARK, Ill., and NEW YORK, March 30, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) and the Local Initiatives Support Corporation (LISC) announced a $37.5 million initiative to provide diverse small businesses with the tailored growth capital, loans and support they need to compete, grow and create jobs. The initiative will support greater diversity in the healthcare industry by advancing a more inclusive supply chain for Abbott and other healthcare companies, while cont…

As the Covid-19 pandemic continues to have a disproportionate impact on women, Organon invites other organisations to join them in their mission to adopt initiatives which help women prioritise their health. LONDON, UK — Organon (NYSE: OGN), a global women’s health company, is designating International Women’s Day (IWD) on 8th March as a day to recognise the growing health disparities that women face that have been exacerbated by the COVID-19 pandemic. Since its inception, IWD has focused on accelerating gender parity. Organon recognises the need for a global effort to address her health and understands that it needs to start with its own employees by giving them paid time off to attend to their own health needs. The company is also inviting organisations in the UK and across the globe to…

Today, 28 February 2022, is Rare Disease Day; the day dedicated to raising awareness for the 300 million people living with a rare disease around the world.  Across the globe, the rare disease community and its supporters are coming together today to share their colours and call for more equitable access to social opportunity, treatment and care for people living with a rare disease and their families. Thousands of events including building illuminations, fundraisers, sporting events, scientific conferences, art exhibitions, policy events and much more are taking place today in over 100 countries! Take a look at the interactive world map of Rare Disease Day events. As part of the Rare Disease Day 2022 campaign, we highlight the stories of 16 superheroes whose experiences represent many of…

Haleon will be a new world-leader in consumer health with an exceptional portfolio of category-leading brands, including Sensodyne, Voltaren, Panadol and Centrum Business is on track to demerge and list as a new company in mid-2022 GlaxoSmithKline plc (GSK) today announced that the new company, to result from the proposed demerger of Consumer Healthcare from GSK in mid-2022, will be called Haleon. Haleon (pronounced "Hay-Lee-On") is inspired by the merging of the words 'Hale', which is an old English word that means 'in good health' and Leon, which is associated with the word 'strength'. The new brand identity was developed with input from employees, healthcare practitioners and consumers and will be deployed in more than 100 markets around the world where the business operates. The crea…

Today is World Encephalitis Day – the global awareness day for people who have been directly or indirectly affected by encephalitis. Founded by The Encephalitis Society in 2014, it has reached over 236 million people through media features, events and social media. Take a look at World Encephalitis Day through the years. What is Encephalitis? Encephalitis is inflammation of the brain and is caused by an infection, or by the immune system attacking the brain. Anyone can be affected by encephalitis, regardless of age, gender, and ethnicity. It has a high death rate, and survivors are often left with brain injuries with life-changing consequences. View more encephalitis facts and figures. How Can You Get Involved? There are three main ways to get involved this World Encephalitis Day: Go #Red…

PARIS--(BUSINESS WIRE)--On the occasion of World Epilepsy Day (14th of February 2022), Angelini Pharma, international Italian pharmaceutical company, is committed to provide patients and healthcare professionals with innovative solutions improving the care of patients with epilepsy. Epilepsy is a common neurological disorder that typically results in seizures of various types, with focal seizures being the most common.1 The essential treatment goal of epilepsy therapy is freedom from seizures.2 The global disease burden of epilepsy is high.3,4 A diagnosis of epilepsy confers significant disability on the individual, including physical, psychological, and social issues that negatively impact self-esteem, family environment, relationships, leisure and working life.3,5 Long-term outcomes for…

To mark World Cancer Day on 4th February, EIT Health vows to back innovative technologies to support early screening and cancer diagnosis EIT Health says that earlier diagnosis will save money on treatment – allowing for savings that can be reinvested into better services Without concerted action, cancer cases are expected to increase by 25 per cent by 2035 making it the leading cause of death in the EU[1] EIT Health, part of the European Institute of Innovation and Technology, today marks World Cancer Day by vowing to back more innovative technologies that can help to support early screening and diagnosis of cancer in a bid to ‘Close the Care Gap’ and help provide equitable care for all. This year’s World Cancer Day’s theme is all about raising awareness of the equity gap that affects…

As the COVID-19 pandemic continues to have a disproportionate impact on women, Organon issues a call to action for other leaders to create opportunities to focus on women’s health in the UK LONDON, UK — Organon (NYSE: OGN), a global women’s health company, is designating International Women’s Day (IWD) on 8th March as a day to recognise the growing health disparities that women face that have been exacerbated by the COVID-19 pandemic. Since its inception, IWD has focused on accelerating gender parity. Organon recognises the need for a global effort to address her health and understands that it needs to start with its own employees by giving them paid time off to attend to their own health needs. The company is also inviting organisations in the UK and across the globe to join in raising aw…

Major new collaboration aims to deepen understanding of complex diseases such as Alzheimer’s and Parkinson’s, and increase drug discovery and development success rates New Institute to be based at Oxford’s Nuffield Department of Medicine GlaxoSmithKline plc and the University of Oxford today announced a major five-year collaboration to establish the Oxford-GSK Institute of Molecular and Computational Medicine. The new Institute, which will be based at the University of Oxford, aims to improve the success and speed of research and development of new medicines, building on insights from human genetics and using advanced technologies such as functional genomics and machine learning. Genetic evidence has already been shown to double success rates in clinical studies of new treatments, and th…

Having claimed 36.3 million lives so far, HIV continues to be a major global public health issue. Although significant progress has been made in recent decades, division, disparity, and disregard for human rights are just some of the failures that have allowed HIV to continue as a global health crisis. COVID-19 has further disrupted the services available to those living with HIV, making this progress even more challenging in recent years. In 2020, 680,000 people died from HIV-related causes, and 1.5 million people acquired HIV. At the end of 2020, there were an estimated 37.7 million people living with HIV, with two thirds of these living in the WHO African Region. The theme of World AIDS Day 2021 is “End inequalities. End AIDS,” aimed at highlighting the growing inequalities in access to…

Vaccine demonstrates protection against COVID-19 related hospitalization and death, and across different variants Toronto ON, 24 November 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has approved its single-shot COVID-19 vaccine to prevent COVID-19 in individuals 18 years of age and older. This decision was based on scientific evidence, including initial data from the Phase 3 ENSEMBLE study that demonstrated the vaccine was 85 percent effective in preventing severe disease, and showed protection against COVID-19 related hospitalization and death, beginning 28 days after vaccination. “We are delighted by Health Canada’s decision to approve the Johnson & Johnson COVID-19 vaccine based on Phase 3 clinical data that proves the v…

- Similac® 360 Total Care® is the first and only infant formula with a blend of five different human milk oligosaccharides[1] (HMOs) across the three categories of HMOs in breast milk[2], the closest prebiotic blend to that of breast milk and previously only available to infants who are breastfed - Similac 360 Total Care with five HMOs is designed to support babies' developing immune system in the gut, where 70% of the immune system resides, promote digestive health and provide building blocks for babies' developing brains ABBOTT PARK, Ill., Nov. 16, 2021 -- Abbott (NYSE: ABT) today announced the launch of Similac 360 Total Care, the company's next generation of infant formula with HMOs, major prebiotics structurally identical to those found in human breast milk. Similac 360 Total Care is…

Rapid test results and certification designed to simplify international arrival Facial recognition and artificial intelligence features increase security and test result confidence Randox, the UK’s largest diagnostics company, today announces that it is launching the Randox CertiFly App, a mobile application designed to securely process and certify results for both pre departure and Day 2 lateral flow tests - the latter a requirement for vaccinated international arrivals in the UK from 24th October. The app, which applies ID verification technology, is designed to simplify foreign travel and facilitate the efficient transfer of secure and verified information through three simple steps: Step 1 – Download the Randox CertiFly App and scan your passport to register Step 2 – Collect your sa…

New UK-listed Consumer Healthcare company to build new global campus and innovation centre in Weybridge, UK GSK unveils longer-term plan to move to new UK headquarters GSK today announced proposals for a major new UK-based headquarters and global campus for the new Consumer Healthcare company following separation in 2022, and its long-term plan for the future headquarters of GSK. New Consumer Healthcare company headquarters to be based in Weybridge, UKThe proposals announced today form part of GSK’s ongoing work to prepare for the separation of the Group into two leading UK-based companies next year – new GSK, a global pharmaceuticals and vaccines company with an R&D approach focused on the science of the immune system, human genetics and advanced technologies, and a world leading Co…

Historic RTS,S/AS01 recommendation can reinvigorate the fight against malaria 6 October 2021 - News release - Geneva The World Health Organization (WHO) is recommending widespread use of the RTS,S/AS01 (RTS,S) malaria vaccine among children in sub-Saharan Africa and in other regions with moderate to high P. falciparum malaria transmission. The recommendation is based on results from an ongoing pilot programme in Ghana, Kenya and Malawi that has reached more than 800 000 children since 2019. “This is a historic moment. The long-awaited malaria vaccine for children is a breakthrough for science, child health and malaria control,” said WHO Director-General Dr Tedros Adhanom Ghebreyesus. “Using this vaccine on top of existing  tools to prevent malaria could save tens of thousands of y…